Honoring Skin Given that over 5 million cases of skin cancer are identified in the US each year, dermatology physicians and Mohs surgeons play a critical role in the diagnosis and treatment of skin cancer.1. In honor of Melanoma and Skin Cancer Awareness Month, Dermatology Times met with a number of prominent skin cancer experts. For instance, the doctors of Harris Dermatology, a practice that solely treats patients with skin cancer, are highlighted in this month’s cover feature.
In Naples and Fort Myers, Florida, brothers Brian Harris, MD, Keith Harris, MD, and H. Ross Harris, MD, provide medical care to patients and assist in the prevention and treatment of skin cancer. The Harris brothers touched on important topics related to skin cancer during their conversation on melanoma and skin cancer awareness month, such as how they provide free skin care to their community.
cancer screenings, the understanding that patients are living longer and hence require ongoing protection against skin cancer, comorbid conditions that may be linked to skin cancer, and more.
A thorough examination of the connection between alcohol use disorder and chronic skin illnesses, which lower quality of life, can also be found in this issue. The significance of screening dermatology patients for alcohol use disorder is discussed by Nicholas Brownstone, MD, a dermatology resident at Temple University Hospital in Philadelphia, Pennsylvania. This is especially important for patients who have been negatively identified by pigmentary disorders and have experienced significant social stigma.
The effectiveness of prebiotic skin care in treating mild atopic dermatitis (AD) and severe xeronic in people with skin of color is investigated by Hawasatu Dumbly, PhD, director of clinical research and medical affairs for La Roche-Posey at L’Oréal USA.
The under researched nature of AD among individuals with skin of color is another issue that Dumbly addresses. among addition, there is a small number of research demonstrating the advantages of emollients in the treatment of AD in a range of people.
As always, Dermatology Times gives our readers access to the most recent clinical content, including FDA approvals, innovative studies, exclusive interviews, and expert insights. To stay up to date on the most recent information, sign up for our e-newsletters, follow us on social media, and send us an email with suggestions or comments at.
Article Source dermatologytimes
